Advertisement

Topics

Latest "The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215" News Stories

11:37 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215" found in our extensive news archives from over 250 global news sources.

More Information about The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215 on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215 for you to read. Along with our medical data and news we also list The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215 Clinical Trials, which are updated daily. BioPortfolio also has a large database of The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215 Companies for you to search.

Showing "Neuropsychiatric Evaluation Positive Negative Drug Using Individuals Study" News Articles 1–25 of 40,000+

Monday 18th March 2019

Cortney Johnson Joins ESO as Chief Financial Officer

Johnson brings experience and expertise managing complex finance strategies for high-growth technology companies ESO, the leading data and software company serving emergency medical services (EMS), fire departments and hospitals, today announced Cortney Johnson has been named Chief Financial Officer. Johnson brings nearly 20 years of financial l...


HAEMATO AG: Preliminary Results 2018

DGAP-News: HAEMATO AG / Key word(s): Preliminary Results 18.03.2019 / 15:14 The issuer is solely responsible for the content of this announcement. Corporate News of HAEMATO AG: HAEMATO AG was able to achieve an EBITDA of EUR 10.0m for the fiscal year 2018 according to preliminary IFRS financial statements. HAEMATO AG, Berlin (ISIN: DE0006190705), achieved consolidated sales of EUR 27...

Catheter ablation for atrial fibrillation no better than drug therapy for reducing death or disabling stroke, trial finds

Catheter ablation achieved no significant reduction in death, disabling stroke, serious bleeding, or cardiac arrest compared with drug treatment in patients with atrial fibrillation (AF) in a large...


Diagnostics Data Analytics Company Diaceutics to List on London Stock Exchange

Company seeking £53M IPO on London Stock Exchange junior market, AIM (Alternative Investment Market) Diaceutics expects the addressable market for its specific services to grow to US$2.5BN by 2023 Diaceutics plc, a revenue-generating and profitable diagnostics data analytics and implementation services company which ...

Sleeping Giant: New Evidence That Narcolepsy Is an Autoimmune Disorder

For centuries, it was thought that individuals who displayed excessive sleepiness, were just not getting the appropriate amount of rest and lifestyle changes were needed to combat these scenarios. Early in the 20th century, physicians and scientists began to realize that some patients who were suffering from excessive tiredness had shared symptomology that was unique […] The post Sleeping Gi...

STAT Plus: A drug maker is hoping that its experimental drug can be used in patients who can’t take a statin because of side effects. #ACC19 https://buff.ly/2Jm8gui 

STAT Plus: A drug maker is hoping that its experimental drug can be used in patients who can’t take a statin because of side effects. #ACC19 https://buff.ly/2Jm8gui 

Imara closes $63M Series B funding round for blood disorder drug development

The company is developing a drug that targets the same pathway as the chemotherapy agent hydroxyurea, but is designed for a better safety profile.

Sterna Biologicals holds Scientific Advisory Board meeting at 14th Congress of ECCO to advance phase IIb clinical development program of SB012 in Ulcerative Colitis

DGAP-News: sterna biologicals GmbH & Co. KG / Key word(s): Miscellaneous 18.03.2019 / 14:00 The issuer is solely responsible for the content of this announcement. STERNA BIOLOGICALS HOLDS SCIENTIFIC ADVISORY BOARD MEETING AT 14th CONGRESS OF ECCO TO ADVANCE PHASE IIb CLINICAL DEVELOPMENT PROGRAM OF SB012 IN ULCERATIVE COLITIS Meeting included international key opinion leaders Inpu...

My Gene Counsel and Ambry Genetics Join Forces to Bridge the Gap Between Direct-to-Consumer Testing and Medical-Grade Genetic Testing

The One-Stop Solution Will Allow Direct-to-Consumer Kit Users to Confirm Their Hereditary Cancer Results NEW HAVEN, Conn. (PRWEB) March 18, 2019 My Gene Counsel, a digital health company that provides personalized, easy-to-understand genetic testing reports, today announced a partnership with Ambry Genetics to offer the first One-Stop Solution for direct-to-consumer (DTC) genetic test results con...

Clinipace Selects TransPerfect’s Trial Interactive E-Feasibility and eTMF Solutions to Support Future Studies

TransPerfect Life Sciences, a leading provider of technologies and services to support clinical trials and product development for the biopharmaceutical industry, today announced that Clinipace has selected TransPerfect’s

Public Voting Begins for Seventh Annual Poster and Video Contest to Raise Awareness for Adolescent Immunization

Artwork from the Top Fifteen New Jersey Middle School and High School Finalists Showcased at ProtectMeWith3.com The Partnership for Maternal and Child Health of Northern New Jersey, in collaboration with the New Jersey Department of Health, today announced the finalists for the seventh annual Protect Me With 3+ immunization awareness contest. Artwork i...

A fish-oil-derived drug sold by Amarin Pharmaceuticals helped prevent not only initial cardiovascular events but also second and third heart attacks, according to a new analysis. #ACC19 https://buff.ly/2TP13XC 

A fish-oil-derived drug sold by Amarin Pharmaceuticals helped prevent not only initial cardiovascular events but also second and third heart attacks, according to a new analysis. #ACC19 https://buff.ly/2TP13XC 

Researchers call on manufacturers to provide excipient allergy info

A study carried out by MIT researchers has found that 93% of medications contain excipients with the potential to cause an allergic reaction.

miR Scientific Presents a New Non-invasive Test for Identifying Clinically Significant Prostate Cancer

New Highly-Sensitive Detection Technology using miRNA and snoRNA Expression Signatures Unveiled at EAU 2019 Proprietary, non-invasive liquid biopsy urine test definitively detects, accurately scores and continuously monitors prostate and bladder cancers miR Scienti

First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes

FARXIGA reduced major adverse cardiovascular events by 16% in patients who had a prior heart attack FARXIGA reduced hospitalization for heart failure regardless of ejection fraction status Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that FARXIGA (dapagliflozin) reduced the relative ri...

Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate

A fish-oil-derived drug sold by Amarin Pharmaceuticals helped prevent not only initial cardiovascular events but also second and third heart attacks, according to a new analysis. #ACC19

STAT Plus: New results show benefits of Esperion’s cholesterol drug — but leave big questions unanswered

A drug maker is hoping that its experimental drug can be used in patients who can’t take a statin because of side effects. #ACC19

They’re Talking. Are You Listening? Improve Your Clinical Trial with Patient Insights, New Webinar Hosted by Xtalks

Early and frequent patient engagement in a clinical trial is instrumental in the launch of new medical products today. Learn how patient insights improves all aspects of clinical trials, from design to feasibility, from experts in clinical operations. TORONTO (PRWEB) March 18, 2019 Early engagement not only improves and makes research studies more cost-effective, but also successfully leverages t...

Peer-Reviewed Paper in Frontiers in Bioengineering and Biotechnology Reveals that uBiome Has the Largest Patent Portfolio in the Microbiome Space

A recent study in Frontiers in Bioengineering and Biotechnology showed uBiome and its executives as top inventors in the microbiome industry. SAN FRANCISCO (PRWEB) March 18, 2019 uBiome, the leader in microbial genomics, has the largest patent portfolio in the microbiome industry and the third highest quality portfolio following Seres Health and Nestle, as published in Frontiers in Bioengineering...

LivaNova Announces Trui Hebbelinck as Chief Human Resources Officer

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Trui Hebbelinck has been appointed Chief Human Resources Officer for the Company. Hebbelinck will lead global human resources, serve on the Executive Leadership Team and report to Chief Executive Officer Damien McDonald. “Trui brings incredible expertise to ...

AscellaHealth Supports Bleeding Disorders Awareness Month, Provides High-Touch Specialty Pharmacy Solutions, Improves Outcomes, Lowers Costs

March is time to raise awareness for rare bleeding disorders and take part in advocacy activities, including social media campaigns World Hemophilia Day is April 17 In recognition of March as

vTv Therapeutics Announces $15 Million of Class A Common Stock Financings

Proceeds Will Fund Start-Up Activities for Current and Future Clinical Trials vTv Therapeutics Inc. (Nasdaq:VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering (the “Registered Direct Offering”) of 3,636,364 shares of...

Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017

LUND, Sweden, March 18, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for the drug candidate ATOR-1017 at the 4th Annu...

State of the European Union: too few API suppliers threaten supply chain

European bio/pharma is living through the “era of the single supplier” for active pharmaceutical ingredients (APIs), contributing to drug shortages,...Read More... The post State of the European Union: too few API suppliers threaten supply chain appeared first on Pharmaceutical Technology.

Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Treatment with neratinib in the approved indication resulted in a 34% reduction in the risk of invasive disease recurrence or death ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks